# Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

> **NCT03415178** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 69 (actual)

## Conditions studied

- Hypercholesterolaemia

## Interventions

- **DRUG:** Alirocumab SAR236553
- **DEVICE:** Current auto-injector device (AI)
- **DEVICE:** New auto-injector device (SYDNEY)
- **DRUG:** Atorvastatin
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT03415178
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-29
- **Primary completion:** 2018-08-09
- **Final completion:** 2018-08-09
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2019-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03415178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03415178, "Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03415178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*